nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2019-6-4-55-61nodgo-554Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESУспешное проведение оперативных вмешательств у пациентов детского возраста с 3-м типом болезни ВиллебрандаSuccessful surgical interventions in pediatric patients with type 3 disease of von WillebrandАндрееваТ. А.AndreevaT. A.

Кандидат медицинских наук, врач-гематолог, заведующая.

191186, Санкт-Петербург, ул. Гороховая, 6

Cand. of Sci. (Med.), Hematologist, Head, Author ID: 954196, SPIN-code: 8529-6758.

6 Gorokhovaya St., S.-Petersburg, 191186

spbhemophilia@mail.ruЛавриченкоИ. А.LavrichenkoI. A.

Врач-гематолог.

191186, Санкт-Петербург, ул. Гороховая, 6

Hematologist.

6 Gorokhovaya St., S.-Petersburg, 191186

КрашенинниковаО. А.KrasheninnikovaO. A.

Врач клинической лабораторной диагностики.

191186, Санкт-Петербург, ул. Гороховая, 6

Clinical Laboratory Diagnostics Docto.

https://orcid.org/0000-0001-7795-8696ГуринаА. К.GurinaA. K.

Студентка 6-го курса педиатрического факультета, SPIN-код: 3711-8953, Author ID: 1038862.

194100, Санкт-Петербург, ул. Литовская, 2

6th year Student of the Faculty of Pediatrics, SPIN-code: 3711-8953, Author ID: 1038862.

2 Litovskaya St., S.-Petersburg, 194100

anastasia_spbgpmu@mail.ruhttps://orcid.org/0000-0002-7718-7593БыковА. А.BykovA. A.

Студент 5-го курса педиатрического факультета СПбГПМУ, SPIN-код: 4437-9031.

194100, Санкт-Петербург, ул. Литовская, 2

5th year Student of the Faculty of Pediatrics, SPIN-code:4437-9031.

2 Litovskaya St., S.-Petersburg, 194100

aleksey.bykov.00@mail.ruhttps://orcid.org/0000-0001-8140-8742НестерчукА. Л.NesterchukА. L.

Студентка 6-го курса педиатрического факультета СПбГПМУ, SPIN-код: 1278-8292.

194100, Санкт-Петербург, ул. Литовская, 2

6th year Student of the Faculty of Pediatrics, SPIN-code: 1278-8292.

2 Litovskaya St., S.-Petersburg, 194100

brownnastya@yandex.ruhttps://orcid.org/0000-0001-8692-0315ПапаянК. А.PapayanK. A.

Карина Альбертовна Папаян - кандидат медицинских наук, доцент кафедры факультетской педиатрии СПбГПМУ, SPIN-код: 7437-0916, Author ID: 783499.

194100, Санкт-Петербург, ул. Литовская, 2

Cand. of Sci. (Med.), Associate Professor Department of Faculty of Pediatrics, SPIN-code: 7437-0916, Author ID: 783499.

2 Litovskaya St., S.-Petersburg, 194100

papayan@inbox.ruАвраменкоВ. В.AvramenkoV. V.

Кандидат медицинских наук, врач-ортопед-травматолог, заведующий хирургическим отделением № 2 СПбГПМУ.

194100, Санкт-Петербург, ул. Литовская, 2

Cand. of Sci. (Med.), Orthopedist-traumatologist, Head ofthe Surgical Department No. 2.

2 Litovskaya St., S.-Petersburg, 194100

https://orcid.org/0000-0001-6977-3966ВеселовА. Г.VeselovA. G.

Кандидат медицинских наук, врач-травматолог-ортопед хирургического отделения № 2 СПбГПМУ, SPIN-код: 7502-2280.

194100, Санкт-Петербург, ул. Литовская, 2

[if !supportLists]A.                 [endif]Cand. of Sci. (Med.), Orthopedist-traumatologist Surgical Department No. 2, SPIN-код: 7502-2280.

2 Litovskaya St., S.-Petersburg, 194100

drveselov@bk.ruЯкунинС. И.YakuninS. I.

Кандидат медицинских наук, врач-детский хирург, заведующий хирургическим отделением Консультативно-диагностического центра СПбГПМУ.

194100, Санкт-Петербург, ул. Литовская, 2

Cand. of Sci. (Med.), Pediatric Surgeon, Head ofthe Surgical Department ofthe Consultative and Diagnostic Center.

Городской центр по лечению больных гемофилией, СПб ГБУЗ Городская поликлиника № 37РоссияCity Center for the Treatment of Hemophilia Patients, City Polyclinic № 37Russian FederationФГБОУ ВО СПбГПМУМинздрава РоссииРоссияSaint-Petersburg State Pediatric Medical University, Ministry of Health of RussiaRussian Federation201922012020645561Copyright © Андреева Т.А., Лавриченко И.А., Крашенинникова О.А., Гурина А.К., Быков А.А., Нестерчук А.Л., Папаян К.А., Авраменко В.В., Веселов А.Г., Якунин С.И., 20202020Андреева Т.А., Лавриченко И.А., Крашенинникова О.А., Гурина А.К., Быков А.А., Нестерчук А.Л., Папаян К.А., Авраменко В.В., Веселов А.Г., Якунин С.И.Andreeva T.A., Lavrichenko I.A., Krasheninnikova O.A., Gurina A.K., Bykov A.A., Nesterchuk А.L., Papayan K.A., Avramenko V.V., Veselov A.G., Yakunin S.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/554

Под нашим наблюдением в клинике СПбГПМУ 2018 по 2019 г. находились 2 пациента детского возраста с болезнью Виллебранда (БВ) 3-го типа, которые нуждались в проведении оперативного лечения. Хирургическое вмешательство проводилось на фоне применения препарата Гемате® П, который используется как для длительной, так и для краткосрочной профилактики при хирургических вмешательствах на фоне БВ. Использование препарата Гемате® Пбыло 100 % эффективным в обоих случаях.

There were two pediatric patients under our supervision at Saint-Petersburg State Pediatric Medical University clinic from 2018 to 2019 with type 3 disease of von Willebrand, who needed the surgical treatment. The surgery was made with Haemate® P which is used as for long-term prophylaxis, as for short-term prophylaxis with surgical treatment for disease of von Willebrand. Application of Haemate® P was 100 % successful in both cases.

педиатриякоагулопатияболезнь Виллебрандагеморрагический синдромэффективность Гемате® Пхирургияортопедияpediatricscoagulopathyvon Willebrand’s diseasehemorrhagic syndromeeffectiveness Haemate® PsurgeryorthopedicsReferencesWindyga J., von Depka-Prondzinski M.; European Wilate® Study Group. Efficacy and safety of a new generation von Willebrand factor/ factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost 2011;105(6):1072–9. doi: 10.1160/TH10-10-0631.Windyga J., von Depka-Prondzinski M.; European Wilate® Study Group. Efficacy and safety of a new generation von Willebrand factor/ factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost 2011;105(6):1072–9. doi: 10.1160/TH10-10-0631.Gill J.C., Lethager S., Di Paola J., Mannucci P., Bernstein J., Manco-Johnson M., Bergman G., Nichols W.L. and the Humate-P Surgery Study Group. Von Willebrand factor/factor VIII (VWF/FVIII) concentrate (Humate-P) for surgical prophylaxis of excessive bleeding in patients with severe von Willebrand disease (VWD). Poster presented at the Meeting of the World Federation of Haemophilia 2006; Poster #898.Gill J.C., Lethager S., Di Paola J., Mannucci P., Bernstein J., Manco-Johnson M., Bergman G., Nichols W.L. and the Humate-P Surgery Study Group. Von Willebrand factor/factor VIII (VWF/FVIII) concentrate (Humate-P) for surgical prophylaxis of excessive bleeding in patients with severe von Willebrand disease (VWD). Poster presented at the Meeting of the World Federation of Haemophilia 2006; Poster #898.Lethagen S., Kyrle P.A., Castaman G., Haertel S., Mannucci P.M. and the Haemate P Surgical Study Group. Von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007;5:1420-30. doi: 10.1111/j.1538-7836.2007.02588.x.Lethagen S., Kyrle P.A., Castaman G., Haertel S., Mannucci P.M. and the Haemate P Surgical Study Group. Von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007;5:1420-30. doi: 10.1111/j.1538-7836.2007.02588.x.Selvam S., James P. Angiodysplasia in von Willebrand disease: Understanding the clinical and basic science. Semin Thromb Hemost 2017;43(6):572-80. doi:10.1055/s-0037-1599145.Selvam S., James P. Angiodysplasia in von Willebrand disease: Understanding the clinical and basic science. Semin Thromb Hemost 2017;43(6):572-80. doi:10.1055/s-0037-1599145.Franchini M., Mannucci P. Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. ThrombHaemost 2014;112:427-31. doi: 10.1160/TH13-11-0952.Franchini M., Mannucci P. Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. ThrombHaemost 2014;112:427-31. doi: 10.1160/TH13-11-0952.Castaman G., Federici A.B., Tosetto A.S., Marca L.A., Stufano F., Mannucci P.M., Rodeghiero F. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost 2012;10(4):632-8. doi: 10.1111/j.1538-7836.2012.04661.x.Castaman G., Federici A.B., Tosetto A.S., Marca L.A., Stufano F., Mannucci P.M., Rodeghiero F. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost 2012;10(4):632-8. doi: 10.1111/j.1538-7836.2012.04661.x.Frankini M., Targher G., Lippi G. Prophylaxis in von Willebrand disease. Ann Hematol 2007;86:699-704. doi: 10.1007/s00277-007-0343-1.Frankini M., Targher G., Lippi G. Prophylaxis in von Willebrand disease. Ann Hematol 2007;86:699-704. doi: 10.1007/s00277-007-0343-1.Gill J.C., Castaman G., Windyga J., Kouides P. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood 2015;126(17):2038-46. doi: 10.1182/blood-2016-04-711259.Gill J.C., Castaman G., Windyga J., Kouides P. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood 2015;126(17):2038-46. doi: 10.1182/blood-2016-04-711259.Scharrer I. Surgery in von Willebrand disease patients. Biomedical Progress 2002;15:18-22. doi: 10.1097/MBC.0000000000000500.Scharrer I. Surgery in von Willebrand disease patients. Biomedical Progress 2002;15:18-22. doi: 10.1097/MBC.0000000000000500.Kurth A.A., Ludwig G., Scharrer I. [Prevalence, pathophysiology, diagnosis and treatment of von Willebrand syndrome in orthopedic trauma patients]. Orthopade 1999;28(4):366-74. doi: 10.1007/PL00003619.Kurth A.A., Ludwig G., Scharrer I. [Prevalence, pathophysiology, diagnosis and treatment of von Willebrand syndrome in orthopedic trauma patients]. Orthopade 1999;28(4):366-74. doi: 10.1007/PL00003619.Oldenburg J., Young G., Santagostino E., Escuriola Ettingshausen C. The importance of inhibitor eradication in clinically complicated hemophilia A patients. Expert Rev Hematol 2018;11(11):857-62. doi: 10.1080/17474086.2018.1521718.Oldenburg J., Young G., Santagostino E., Escuriola Ettingshausen C. The importance of inhibitor eradication in clinically complicated hemophilia A patients. Expert Rev Hematol 2018;11(11):857-62. doi: 10.1080/17474086.2018.1521718.Lassila R., Holme P.A., Landorph A., Petrini P., Onundarson P.T., Hillarp A. Semin Thromb Hemost 2011;37:495-502. PMID: 22102192.Lassila R., Holme P.A., Landorph A., Petrini P., Onundarson P.T., Hillarp A. Semin Thromb Hemost 2011;37:495-502. PMID: 22102192.Berntorp E., Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005;16(Suppl. 1):S23-S26. doi:10.1097/01.mbc.0000167659.23262.18.Berntorp E., Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005;16(Suppl. 1):S23-S26. doi:10.1097/01.mbc.0000167659.23262.18.Lethagen S. Clinical experience of prophylactic treatment in von Willebrand disease. Thromb Res 2006;118(Suppl. 1):S9-S11. doi: 10.1016/j.thromres.2006.01.021.Lethagen S. Clinical experience of prophylactic treatment in von Willebrand disease. Thromb Res 2006;118(Suppl. 1):S9-S11. doi: 10.1016/j.thromres.2006.01.021.Berntorp E., Abshire T.; vWD Steering Committee. The von Willebrand disease prophylaxis network (VWD PN): exploring a treatment concept. Thromb Res 2006;118 Suppl. 1: S19-S22. doi: 10.1016/j.thromres.2006.01.016.Berntorp E., Abshire T.; vWD Steering Committee. The von Willebrand disease prophylaxis network (VWD PN): exploring a treatment concept. Thromb Res 2006;118 Suppl. 1: S19-S22. doi: 10.1016/j.thromres.2006.01.016.

The authors declare that there are no conflicts of interest present.